NVO
Novo Nordisk A/S
NVO has lower modeled downside risk, despite its lower overall score.
OPRX
OptimizeRx Corporation
OPRX has the edge over NVO overall, supported by stronger fundamentals and stronger valuation.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
OPRX Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Healthy | |
| Strong | |
| Strong |
OPRX's profitability, cash flow and balance sheet are currently healthy, but its revenue is under pressure.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO has the edge over OPRX in the historical PE scenario, which offers more potential upside but is not a forecast.
OPRX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 9.2x | $8.87 | — |
| Cheap | 20x | $4.88 | -45% |
| Current | 37x | $8.87 | — |
| Fair | 592x | $142 | +1503% |
| Expensive | 1,627x | $391 | +4303% |
Historical ranges are pointers, not guarantees.
OPRX's PE is in its fair range at 37x. If earnings grow as analysts expect, today's price would be 9.2x next year's earnings, in its cheap range.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
OPRX Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OPRX has the edge over NVO on the outlook, with more favorable earnings and profitability expectations.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over OPRX on earnings, with more consistent year-over-year improvement.
OPRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.97 | +304% |
| Q2 2026 | $0.24 | +$0.78 |
| Q1 2026 | $0.36 | +$1.20 |
| Q4 2025 | $0.27 | +$1.37 |
| Q3 2025 | $0.00 | +$1.35 |
| Q2 2025 | -$0.54 | +$0.48 |
| Q1 2025 | -$0.84 | +$0.20 |
| Q4 2024 | -$1.10 | -$0.07 |
| Q3 2024 | -$1.35 | -$0.54 |
OPRX has returned to profit: it earned $0.24 per share over the past year, after losing money the year before.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over OPRX on profitability, with a higher operating margin.
OPRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $20.5M | -30% |
| Q1 2026 | $19.8M | -9.5% |
| Q4 2025 | $32.2M | -0.2% |
| Q3 2025 | $26.1M | +22% |
| Q2 2025 | $29.2M | +2307% |
| Q1 2025 | $21.9M | +1168770% |
| Q4 2024 | $32.3M | +14% |
| Q3 2024 | $21.3M | +30% |
OPRX's revenue has slid since its 2024 peak: $21M last quarter, down 30% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -0.4% | -11 points |
| Q1 2026 | 2% | +12 points |
| Q4 2025 | 27% | +15 points |
| Q3 2025 | 7.9% | +48 points |
| Q2 2025 | 11% | +320 points |
| Q1 2025 | -9.6% | +268061 points |
| Q4 2024 | 11% | +50 points |
| Q3 2024 | -40% | -18 points |
OPRX's operating margin was −0.4% last quarter, down 11 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
OPRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $8.6M | +88% |
| Q1 2026 | -$488K | -113% |
| Q4 2025 | $7.1M | +3810% |
| Q3 2025 | $3.2M | +80% |
| Q2 2025 | $4.6M | +518% |
| Q1 2025 | $3.8M | +84% |
| Q4 2024 | $181K | +$6.4M |
| Q3 2024 | $1.8M | +23% |
OPRX has the edge over NVO on cash flow, with more consistent year-over-year improvement.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has 4.4B diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
OPRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +24K shares |
| 1 year | -1.2% | -230K shares |
| 3 years | +11% | +1.8M shares |
| 5 years | +3.8% | +681K shares |
| Available history | +33% | +4.6M shares |
OPRX has the edge over NVO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2023 | — |
| Q2 2023 | $7.5M |
| Q4 2022 | $7.5M |
| Q3 2022 | $12.2M |
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
OPRX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | -0.3x | Net Cash |
| Q1 2026 | 0.2x | Very low |
| Q4 2025 | 0.1x | Very low |
| Q3 2025 | 0.8x | Very low |
| Q2 2025 | 23.5x | High |
OPRX has the edge over NVO on leverage, with a lower net debt burden relative to earnings.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
OPRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.0 | Neutral |
| Stochastic | 77.6 | Neutral |
OPRX's weekly RSI is 57 (neutral) and its Stochastic is 78 (neutral).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO has the edge over OPRX on valuation relative to its sector.
OPRX PE vs Healthcare Sector
| Metric | OPRX | Sector median | Relative |
|---|---|---|---|
| PE | 37x | 26x | 43% above |
| PE % | 45 | 29 | 16 pts above |
OPRX is trading at 37x earnings, a 43% premium to the Healthcare sector's median of 26x.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
OPRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $8.69 | 2.1% above |
| 20 week MA | $7.75 | 14% above |
| 50 week MA | $8.11 | 9.4% above |
| 100 week MA | $10.1 | 12% below |
| 200 week MA | $10.7 | 17% below |
OPRX has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over OPRX on returns for 2026, with the stronger performance.
OPRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $10.1 | $31.6 | +214% |
| 2021 | $31.6 | $60.5 | +92% |
| 2022 | $60.5 | $16.7 | -72% |
| 2023 | $16.7 | $14.3 | -14% |
| 2024 | $14.3 | $5.09 | -64% |
| 2025 | $5.09 | $12.5 | +145% |
| 2026 YTD | $12.5 | $8.87 | -29% |
OPRX's yearly returns have swung widely, from +214% in 2020 to −72% in 2022. It's down 29% so far in 2026.